FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
FDA Office of Acquisitions and Grants Services
Contract Value
Not provided
Codes & Classification
Solicitation Number
FDABAA-26-00123
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Classification Code
AJ11
Additional Details
Documents5
The U.S. Food and Drug Administration (FDA), under the Department of Health and Human Services, has issued a Broad Agency Announcement (BAA) for Fiscal Year 2026, inviting proposals for advanced research and development in regulatory science. This opportunity, identified as FDABAA-26-00123, is managed by the FDA Office of Acquisitions and Grants Services, located in Silver Spring, Maryland.
The primary objective of this BAA is to solicit innovative basic and applied research projects that will advance scientific knowledge in areas critical to the FDA’s mission of protecting and promoting public health. The scope encompasses a wide range of research and development activities, specifically targeting regulatory science and innovation. The FDA seeks to fund extramural research that addresses defined research areas and sub-areas of interest, as detailed within the BAA documentation. These efforts are intended to support the agency’s ongoing commitment to scientific advancement and regulatory excellence.
Key requirements for this procurement include the submission of proposals that align with the FDA’s strategic priorities in regulatory science. While the Product Service Code (PSC) AJ11—pertaining to general research and development in health—has been specified, the FDA notes that proposals are not restricted solely to this code, allowing for a broader range of scientific disciplines and approaches. The applicable NAICS code is 541714, which covers Research and Development in Biotechnology (except Nanobiotechnology), reflecting the agency’s focus on cutting-edge biotechnological research.
The place of performance for awarded projects is Silver Spring, Maryland, though the BAA may accommodate a variety of research settings depending on the nature of the proposed work. The contracting entity is the FDA Office of Acquisitions and Grants Services, a federal office responsible for managing research funding and procurement activities.
This procurement is classified as a Special Notice and is conducted in accordance with FAR 6.102(d)(2) and 35.016, which govern the use of BAAs for acquiring research and development. The announcement has undergone several amendments, with the latest version (2.0) highlighting updated requirements and clarifications. Interested parties are encouraged to review the highlighted changes in the current announcement document.
A notable event associated with this opportunity is the FY26 Virtual BAA Day, scheduled for January 20, 2026. This event will provide prospective offerors with additional information and guidance regarding the BAA and proposal submission process. Details and registration information are available on the FDA’s regulatory science webpage.
The notice remains active, with a response deadline of February 24, 2026. Contractors considering this opportunity should ensure their capabilities align with the FDA’s research priorities and the requirements outlined in the BAA. For further information or specific inquiries, the primary point of contact is Ian Weiss, who can be reached at [email protected] or by phone at 301-796-5728.
In summary, this BAA represents a significant opportunity for organizations engaged in biotechnology research and regulatory science to contribute to the FDA’s mission through innovative research and development projects. The agency seeks proposals that demonstrate scientific rigor, relevance to regulatory science, and the potential to impact public health outcomes.